Enlivex Therapeutics/$ENLV
1D1W1MYTD1Y5YMAX
Capital at risk
About Enlivex Therapeutics
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
- Ticker
- $ENLV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Ness Ziona, Israel
- Website
- www.enlivex.com
ENLV Metrics
BasicAdvanced
$13M
0.00
$382.20
1.52
-
Price and volume
Market cap
$13M
Beta
1.52
Financial strength
Current ratio
193.236
Quick ratio
0.694
Long term debt to equity
0
Total debt to equity
0
Profitability
EBITDA (TTM)
-14.668
Effective tax rate (TTM)
23.65%
Management effectiveness
Return on assets (TTM)
-0.80%
Return on equity (TTM)
126.17%
Valuation
Price to earnings (TTM)
0.002
Price to book
0.01
Price to tangible book (TTM)
0.01
Price to free cash flow (TTM)
-0.211
Free cash flow yield (TTM)
-473.26%
Free cash flow per share (TTM)
-3.441
Growth
Earnings per share change (TTM)
-3,581.39%
3-year earnings per share growth (CAGR)
147.11%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.